Transform your Antibody Discovery Pipeline

Try for FreeLearn More

Meet the industry’s leading cloud-based antibody discovery platform

Select the best candidate antibodies with intuitive sequence annotation and analysis tools. Be sure to extract maximum value from your antibody sequence datasets with Geneious Biologics.

Innovative Algorithms, Unprecedented Accuracy

Annotate and validate your sequences with easy-to-use, accurate, and scalable analytics pipelines.

Our streamlined, configurable workflows ensure consistent and reliable results.

Accelerated Candidate Selection

Significantly speed up candidate selection by leveraging datasets of all sizes, from Sanger to NGS to Single Cell.

All sequence data can be imported, assembled, annotated and analyzed in a single collaborative workspace.

Superior Visualizations

Unlock valuable insights with interactive visualizations, statistics, and search tools.

Explore clonotypes, discover patterns, and generate rich visualizations by combining sequences, trees, liabilities and assay data.

Explore Geneious Biologics

Annotate and Validate
  • Annotate, validate, and characterize IgG-like antibody sequences
  • Identify CDR regions, liabilities, germline gene variants and other sequence features
  • Export intuitive visualizations and tables for sharing and reporting

Learn More > 

Data Security
Data integrity and security is of utmost importance and we are committed to ensuring customer data is hosted in the most secure environment possible.

Learn More > 

Advanced Analytics
Explore large NGS datasets with intuitive graphs and statistics. Compare frequencies and filter down to find the best individual candidates.

Learn More > 

Helping global biotech leaders accelerate antibody discovery and screening

“IONTAS had a requirement for processing large quantities of data from both our service based antibody discovery projects and our internal developments. Geneious Biologics delivered a software solution that has significantly improved the efficiency and scope of our sequence analysis workflows during therapeutic antibody discovery.”

– Peter Slavny, Group Leader at IONTAS